[
  {
    "ts": null,
    "headline": "China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order",
    "summary": "Biotech stocks Zai Labs and BeOne Medicines plummeted Wednesday on reports President Donald Trump will issue an executive order to reduce U.S. access to drugs developed in China.",
    "url": "https://finnhub.io/api/news?id=6fea7084a16337cbfa7762f92e4a469ee47576d02d1578c994f49e37f8fdc884",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757537758,
      "headline": "China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order",
      "id": 136689352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Biotech stocks Zai Labs and BeOne Medicines plummeted Wednesday on reports President Donald Trump will issue an executive order to reduce U.S. access to drugs developed in China.",
      "url": "https://finnhub.io/api/news?id=6fea7084a16337cbfa7762f92e4a469ee47576d02d1578c994f49e37f8fdc884"
    }
  },
  {
    "ts": null,
    "headline": "Trump’s Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.",
    "summary": "A new Trump administration crackdown on prescription drug ads directed at consumers could substantially drag on pharmaceutical revenues—if it’s successful at reining in the billions of dollars that drug companies spend on ads each year in the U.S.  It remains unclear what impact these government measures will have on direct-to-consumer drug ads—on which drugmakers spend more than $10 billion a year in the U.S.  U.S. courts have held that the ads are shielded by First Amendment speech protections, but in a note to investors late Tuesday, Raymond James healthcare policy analyst Chris Meekins wrote that the administration looks to be trying to kill drug advertising with “disclosure and rule-making.”",
    "url": "https://finnhub.io/api/news?id=83781c4c6edbf9d5214a2a3bd1c314075e02f999ffa209003a3348c114a1f94d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757533740,
      "headline": "Trump’s Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.",
      "id": 136688576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A new Trump administration crackdown on prescription drug ads directed at consumers could substantially drag on pharmaceutical revenues—if it’s successful at reining in the billions of dollars that drug companies spend on ads each year in the U.S.  It remains unclear what impact these government measures will have on direct-to-consumer drug ads—on which drugmakers spend more than $10 billion a year in the U.S.  U.S. courts have held that the ads are shielded by First Amendment speech protections, but in a note to investors late Tuesday, Raymond James healthcare policy analyst Chris Meekins wrote that the administration looks to be trying to kill drug advertising with “disclosure and rule-making.”",
      "url": "https://finnhub.io/api/news?id=83781c4c6edbf9d5214a2a3bd1c314075e02f999ffa209003a3348c114a1f94d"
    }
  },
  {
    "ts": null,
    "headline": "5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds",
    "summary": "In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.",
    "url": "https://finnhub.io/api/news?id=53beb53f11265427115a0250ab7c4556b4541be721f51f199478620ba03e385e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757520480,
      "headline": "5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds",
      "id": 136688580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.",
      "url": "https://finnhub.io/api/news?id=53beb53f11265427115a0250ab7c4556b4541be721f51f199478620ba03e385e"
    }
  },
  {
    "ts": null,
    "headline": "J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum",
    "summary": "J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.",
    "url": "https://finnhub.io/api/news?id=1c6b7357ed95e1f906ff01a9c73662da70f04a51d4529120bacc2c8e3e24db5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757520120,
      "headline": "J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum",
      "id": 136688660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.",
      "url": "https://finnhub.io/api/news?id=1c6b7357ed95e1f906ff01a9c73662da70f04a51d4529120bacc2c8e3e24db5a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer-Olema Collaboration Targets Metastatic Breast Cancer",
    "summary": "Pfizer Inc. (NYSE:PFE) is among the undervalued wide moat stocks to buy now. Olema Pharmaceuticals has announced its collaboration and supply agreement with Pfizer Inc. (NYSE:PFE) in the treatment of metastatic breast cancer. Under the clinical trial partnership, both companies will examine the palazestrant-atirmociclib combination in approximately 35 patients, anticipated to begin in H2 2025. […]",
    "url": "https://finnhub.io/api/news?id=2ffaaabd83660e3ba9b3c72d2c7ae257d50ee0d75d6df8c5cffe5f1a36f4397b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757499478,
      "headline": "Pfizer-Olema Collaboration Targets Metastatic Breast Cancer",
      "id": 136689356,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is among the undervalued wide moat stocks to buy now. Olema Pharmaceuticals has announced its collaboration and supply agreement with Pfizer Inc. (NYSE:PFE) in the treatment of metastatic breast cancer. Under the clinical trial partnership, both companies will examine the palazestrant-atirmociclib combination in approximately 35 patients, anticipated to begin in H2 2025. […]",
      "url": "https://finnhub.io/api/news?id=2ffaaabd83660e3ba9b3c72d2c7ae257d50ee0d75d6df8c5cffe5f1a36f4397b"
    }
  },
  {
    "ts": null,
    "headline": "Health Officials Hunt for Cases Connecting Covid Shot and Harm in Pregnant Women",
    "summary": "Top health officials under Robert F. Kennedy Jr. are compiling examples of harmful effects of Covid shots on pregnant women to share with the public, furthering the administration’s scrutiny of vaccines.",
    "url": "https://finnhub.io/api/news?id=f44fb8a85f855b0079f79e00cc7bd4de8f6138dc29c62a5ef5f21c035399ae2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757466000,
      "headline": "Health Officials Hunt for Cases Connecting Covid Shot and Harm in Pregnant Women",
      "id": 136689357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Top health officials under Robert F. Kennedy Jr. are compiling examples of harmful effects of Covid shots on pregnant women to share with the public, furthering the administration’s scrutiny of vaccines.",
      "url": "https://finnhub.io/api/news?id=f44fb8a85f855b0079f79e00cc7bd4de8f6138dc29c62a5ef5f21c035399ae2c"
    }
  }
]